All News
Filter News
Found 1,164 articles
-
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
5/12/2022
Aptose Biosciences Inc. announced that the company management team, along with guest key opinion leaders, will provide an update for the investment community on Thursday, June 2nd at 4:30 PM.
-
Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19.
-
Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.
-
ImmunoGen, which is developing Antibody-drug conjugates (ADCs) for the treatment of cancer, is on a hiring spree. The company is looking to hire for more than 200 positions by the end of 2022.
-
ADC Therapeutics Announces CEO Transition
5/9/2022
ADC Therapeutics SA announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer.
-
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer
5/9/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), today announced that the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab (Tencentriq®) during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer (ES-SCLC).
-
Thermo Fisher Scientific to Present at BofA Securities 2022 Healthcare Conference
5/6/2022
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 12:20 p.m. (EDT).
-
After the market closed on Wednesday, Allogene reported its first-quarter financial results, along with updates to its research programs. The report marked Allogene's fourth anniversary.
-
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
5/5/2022
BioMarin Pharmaceutical Inc. announced that the Company hired two pharmaceutical industry leaders in their respective areas of expertise.
-
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
5/5/2022
BioMarin Pharmaceutical Inc. today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.
-
Florida Institute and MPWRM Resource Center Fund Amend Surgical
5/4/2022
Amend Surgical, Inc. announced that it has finalized a funding agreement with the Institute for Commercialization of Florida Technology along with being awarded a substantial product development funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center.
-
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
5/4/2022
BioMarin Pharmaceutical Inc., announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the BofA Securities Healthcare Conference on May 12 at 8:40am PT/11:40am ET in Las Vegas.
-
The Q1 results for Voxzogo gave BioMarin the confidence to raise its 2022 full-year guidance to between $100 million to $125 million (net product revenue) for the drug.
-
Thermo Fisher Scientific Reports First Quarter 2022 Results
4/28/2022
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the first quarter ended April 2, 2022.
-
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
4/27/2022
Allogene Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to ALLO-605, the Company’s next-generation AlloCAR T product candidate targeting BCMA for the treatment of multiple myeloma.
-
BioMarin Announces Record Revenues in First Quarter 2022
4/27/2022
BioMarin Pharmaceutical Inc. announced financial results for the first quarter ended March 31, 2022.
-
Acadia Pharmaceuticals faces a major hurdle after top-line results from its study of ACP-044 for post-surgery pain failed to meet desired outcomes.
-
LogicMark Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results
4/19/2022
LogicMark, Inc. announces financial and operating results for the fourth quarter and full year ended December 31, 2022.
-
Ichnos Sciences Welcomes Ashok Marín As New General Counsel
4/19/2022
Ichnos Sciences Inc., a global biotechnology company developing innovative multispecific antibodies for oncology, announced the appointment of Ashok Marín, Esq., to the position of General Counsel, effective immediately.
-
The new facility is expected to bolster innovation across all facets of manufacturing to allow the company to fully develop and commercialize cancer treatments for patients in need.